-

GE HealthCare unveils enhanced Voluson Expert Series women’s health ultrasound systems with focus on early detection and exam efficiency

  • Latest Voluson Expert 22, 20 and 18 ultrasound systems harness artificial intelligence and advanced tools and software for more efficient assessments
  • Voluson Expert Series delivers elevated performance, with focus on first trimester to reveal clearer anatomical details, aiding earlier detection and boosting diagnostic confidence

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the updated portfolio of Voluson™ Expert Series ultrasound systems. Voluson Expert 22, 20 and 18 combine high resolution image quality with advanced ultrasound technology and an ergonomic design for efficient workflow and a world-class user experience. The Voluson Expert Series integrates artificial intelligence (AI)-powered features and automation tools to help drive imaging performance and efficiencies in women’s healthcare.

Approximately 30,000 to 50,000 women in the United States experience complex, high-risk pregnancy each year.i When these complications are left undetected or untreated, it may harm the mother or the baby. The growing prevalence of these complicationsii underscores the need for innovative solutions that enable early detection and intervention.

The Voluson Expert Series, GE HealthCare’s most advanced women’s health ultrasound systems, offers premium ultrasound imaging for confident diagnoses for high risk, complex pregnancies. The Lyric Architecture is designed to unlock new imaging and processing power to deliver detailed and uniform images and reveal finer details within the anatomy with ease, even in difficult scanning conditions. AI-enabled functionality and automation tools are available to support faster assessments and early detection, diagnosis and intervention.

The SonoLyst suite of AI tools were designed to simplify exams through image recognition and automated annotations and measurements, increasing exam speed and accuracy. With this new release, clinicians can now utilize SonoLystlive during 11 to 14-week anatomical exams helping ensure required views are captured for diagnostic accuracy.  In addition, Voluson Expert Series ultrasound systems feature an expanded color Doppler offering, Graphicflow, which provides a graphical representation of the trajectories of the blood cells in real-time to visualize complex blood flow quickly and clearly, helping users differentiate normal from abnormal hemodynamics.

Voluson Expert Series also includes additional enhancements to select Voluson AI tools:

  • SonoPelvicFloor3.0 can help reduce pelvic floor measurement exam time by 80%.* This feature now expands anatomical views, and simplifies the exam process by automating plane alignment, live C-plane tracking, and measurements.
  • SonoAVCfollicle2.0 uses AI to increase accuracy and precision in follicle detection, resulting in a better success rate of detecting follicles, along with reduced artifacts and requiring less time for postprocessing.

These systems are compatible with a wide selection of unique specialty probes, including a new lightweight 2D/3D probe RAB7-D, and wireless Vscan Air™ dual probes.

“We are proud to introduce these updates to the Voluson Expert ultrasound systems, which represent our ongoing commitment to advancing technology that addresses women's health needs of today, and the future,” said Gerald Seifriedsberger, General Manager, Women’s Health, Advanced Visualization Solutions, GE HealthCare. “By introducing solutions that offer unparalleled clarity and detail, we can empower users with critical insights for informed care decisions and efficient exams, transforming how clinicians approach healthcare. Together, we can create a healthier future for all women.”

GE HealthCare will showcase the Voluson Expert series ultrasound systems at the Society for Maternal-Fetal Medicine (SMFM) 2025 Pregnancy Meeting™ taking place on January 27-February 1 in Denver. The Voluson Expert Series is available in the United States. For more information on the Voluson Expert Series, visit: https://www.gehealthcare.com/products/ultrasound/voluson.

*Versus manual exam

___________________________________

i Cleveland Clinic. High-Risk Pregnancy. Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/22190-high-risk-pregnancy. Last reviewed July 12, 2024. Accessed January 17, 2025.

ii Barfield WD, Besera G, Cox S, Warner L, Azeez O, Riggs J, Russell R, Bowron S, Churchill RE. From Data to Action: CDC's Public Health Surveillance for Women, Infants, and Children. 2nd ed. Centers for Disease Control and Prevention; 2020. https://www.cdc.gov/reproductive-health/media/pdfs/data-to-action/Data-To-Action_508.pdf. Accessed January 17, 2025.

 

Contacts

Eric Tatro
Media Contact
GE HealthCare
+1 312 459 6140
Eric.Tatro@gehealthcare.com

GE HealthCare

NASDAQ:GEHC

Release Versions

Contacts

Eric Tatro
Media Contact
GE HealthCare
+1 312 459 6140
Eric.Tatro@gehealthcare.com

More News From GE HealthCare

Catholic Health and GE HealthCare partner to expand patient access across Long Island

ROCKVILLE CENTRE, N.Y.--(BUSINESS WIRE)--Catholic Health, an integrated health system located on Long Island, NY, and GE HealthCare (Nasdaq: GEHC) announced today a 10-year strategic partnership, known as a Care Alliance, valued at approximately $500 million, to help expand access to advanced imaging, precision diagnostics and AI-enabled technology across Catholic Health in support of innovative, compassionate and patient-centered care. This will be one of the largest Care Alliances between GE...

GE HealthCare and Mayo Clinic aim to advance personalized cancer treatment through new theranostics research collaboration

CHICAGO & ROCHESTER, Minn.--(BUSINESS WIRE)--GE HealthCare and Mayo Clinic today announced the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) research collaboration, a novel theranostics study designed to explore a more personalized approach to radioligand therapy (RLT) for patients with advanced prostate cancer. This collaboration is a direct result of the 2023 Strategic Radiology Research Alliance between Mayo Clinic and GE HealthCare, aimed at transforming the experience of...

GE HealthCare to announce second quarter 2026 results on July 29, 2026

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will announce its second quarter 2026 financial results before the market opens on Wednesday, July 29, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will...
Back to Newsroom